Optical Coherence Tomography Assessment of Intimal Tissue and Malapposition: A Randomized Comparison of the Biolimus A9-eluting and Everolimus-eluting Coronary Stents.

Trial Profile

Optical Coherence Tomography Assessment of Intimal Tissue and Malapposition: A Randomized Comparison of the Biolimus A9-eluting and Everolimus-eluting Coronary Stents.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 14 Aug 2014

At a glance

  • Drugs Umirolimus (Primary) ; Everolimus
  • Indications Acute coronary syndromes; Angina pectoris; Coronary artery disease; Coronary artery restenosis; Ischaemic heart disorders; Myocardial infarction
  • Focus Therapeutic Use
  • Acronyms OPTIMA
  • Most Recent Events

    • 02 Aug 2014 Planned End Date changed from 1 Jun 2012 to 1 Dec 2014 as reported by ClinicalTrials.gov record.
    • 02 Aug 2014 Planned primary completion date changed from 1 Oct 2011 to 1 Dec 2014 as reported by ClinicalTrials.gov record.
    • 02 Aug 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top